12:00 AM
Mar 22, 1999
 |  BC Week In Review  |  Clinical News  |  Clinical Status

NBI-6024: Began Phase I testing

Neurocrine Biosciences Inc. (NBIX), San Diego, Calif.
Product: NBI-6024
Business: Metabolic
Therapeutic category: Immune modulation
Target: NA...

Read the full 61 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >